12 results
The primary objective of this study is to investigate the improvement of masticatory function of implant-supported RPD treatment in free-ending, bilateral mandibular partial edentulism. The secondary objectives include patient satisfaction (OHIP14…
To perform a pilot study to determine the feasibility of conducting a two-arm phase I trial and to determine the recommended dose level for phase II (RP2D) study and assess the safety of the combination olaparib and melphalan in patients with…
To investigate the influence of platform-switched implant-abutment connections (smaller diameter abutment on wider diameter implant) of short implants (8.5 mm in length) on marginal peri-implant bone levels and clinical variables.
To investigate the influence of short implants (6 mm in length) on marginal peri-implant bone levels, clinical variables and patient satisfaction.
The aim of this study to evaluate the clinical performance of short implants (4 mm in length) in the resorbed posterior mandibular region of partially edentulous patients that will be restored with a single crown.
• To evaluate the effect of olaparib on exposure to anastrozole by determination of steady-state exposure to anastrozole in the presence and absence of steady-state exposure to olaparib• To evaluate the effect of anastrozole on exposure to olaparib…
Primary objective: to define the maximal tolerated dose (MTD) of Olaparib in combination with high dose radiotherapy with and without daily dose cisplatin in locally advanced non-small cell lung carcinoma.
To investigate the influence of different implant neck designs on marginal peri-implant bone levels and clinical variables.
The primary purpose of the study is to determine the efficacy of AZD2281 compared to placebo in serous ovariancancer platinum sensitive patients and in a defined HRD subset.
To define the maximal tolerated dose (MTD) of olaparib in combination with radiotherapy in laryngeal and oropharyngeal SCC.
To define the maximal tolerated dose (MTD) of olaparib in combination with radiotherapy of the breast and regional lymph nodes in patients with breast cancer without the use of skin bolus (arm A) or with the use of skin bolus (arm B).
To determine the efficacy (as assessed by rPFS) and safety of olaparib versus investigator choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal…